

Table O.46: Withdrawal of zuclopenthixol versus continuation of zuclopenthixol in adults

| Quality assessment | | | | | | | Summary of findings | | | | |
|--|----------------------|--------------------------|-------------------------|---------------------------|------------------|---|-------------------------------------|-----------------------------------|--------------------------|--|--|
| Participants (studies) Follow up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall quality of evidence | Study event rates (%) | | Relative effect (95% CI) | Anticipated absolute effects | |
| | | | | | | | With continuation of zuclopenthixol | With withdrawal of zuclopenthixol | | Risk with continuation of zuclopenthixol | Risk difference with withdrawal of zuclopenthixol (95% CI) |
| Targeted behaviour that challenges (relapse) – post-treatment | | | | | | | | | | | |
| 39 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision | 12/19 (63.2%) | 19/20 (95%) | RR 1.5 (1.05 to 2.15) | 632 per 1000 | 316 more per 1000 (from 32 more to 726 more) |
| Targeted behaviour that challenges (severity) – post-treatment (measured with: End-point score; Better indicated by lower values) | | | | | | | | | | | |
| 39 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊕⊕⊕ VERY LOW ^{1,2} due to risk of bias, imprecision | 19 | 20 | - | | The mean targeted behaviour that challenges (severity) – post-treatment in the intervention groups was 0.56 standard deviations higher |

| | | | | | | | | | | | | |
|---|----------------------|--------------------------|-------------------------|---------------------------|------------|---|-----------------|-----------------|-----------------------------|-----------------|--|--|
| | | | | | | | | | | | | (0.08 lower to 1.2 higher) |
| Targeted behaviour that challenges (severity) – post-treatment (measured with: Change score; Better indicated by lower values) | | | | | | | | | | | | |
| 85 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊖⊖⊖ VERY LOW ^{1,2} due to risk of bias, imprecision | 45 | 40 | - | | | The mean targeted behaviour that challenges (severity) – post-treatment in the intervention groups was 0.68 standard deviations higher (0.24 to 1.11 higher) |
| Targeted behaviour that challenges (problems in management) – post-treatment | | | | | | | | | | | | |
| 43 (1 study) | serious ³ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊖⊖⊖ VERY LOW ^{2,3} due to risk of bias, imprecision | 5/24 (20.8%) | 7/19 (36.8%) | RR 1.77 (0.67 to 4.7) | 208 per 1000 | | 160 more per 1000 (from 69 fewer to 771 more) |
| Adaptive functioning (social) – post-treatment (Better indicated by higher values) | | | | | | | | | | | | |
| 85 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊖⊖⊖ VERY LOW ^{1,2} due to risk of bias, imprecision | 45 | 40 | - | | | The mean adaptive functioning (social) – post-treatment in the intervention groups was 0.47 standard deviations lower (0.9 to 0.04 lower) |
| Adverse events (weight gain; kg) – post-treatment (Better indicated by lower values) | | | | | | | | | | | | |
| 39 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊖⊖⊖ VERY LOW ^{1,2} due to risk of bias, imprecision | 19 | 20 | - | | | The mean adverse events (weight gain; kg) – post-treatment in the intervention groups was 0.55 standard |

| | | | | | | | | | | | | |
|--|----------------------|------------------------------|----------------------------|------------------------------|------------|--|-------------------|-------------------|------------------------------------|-----------------|---|--|
| | | | | | | | | | | | | deviations lower (1.19 lower to 0.09 higher) |
| Adverse events (drowsiness, non-occurrence) – post-treatment | | | | | | | | | | | | |
| 42 (1 study) | serious ¹ | no serious inconsistency | no serious indirectness | very serious ² | undetected | ⊕⊖⊖⊖ VERY LOW ^{1,2} due to risk of bias, imprecision | 19/20 (95%) | 21/22 (95.5%) | RR 1 (0.88 to 1.15) | 950 per 1000 | 0 fewer per 1000 (from 114 fewer to 142 more) | |
| Adverse events (discontinuation due to adverse events, non-occurrence) – post-treatment | | | | | | | | | | | | |
| 204 (3 studies) | serious ⁴ | serious ⁵ | no serious indirectness | serious ⁶ | undetected | ⊕⊖⊖⊖ VERY LOW ^{4,5,6} due to risk of bias, inconsistency, imprecision | 98/103 (95.1%) | 80/101 (79.2%) | RR 0.86 (0.71 to 1.04) | 951 per 1000 | 133 fewer per 1000 (from 276 fewer to 38 more) | |
| Adverse events (discontinuation due to other reasons, non-occurrence) – post-treatment | | | | | | | | | | | | |
| 91 (2 studies) | serious ⁴ | very serious ⁷ | no serious indirectness | serious ⁶ | undetected | ⊕⊖⊖⊖ VERY LOW ^{4,6,7} due to risk of bias, inconsistency, imprecision | 38/46 (82.6%) | 29/45 (64.4%) | RR 0.73 (0.33 to 1.64) | 826 per 1000 | 223 fewer per 1000 (from 553 fewer to 529 more) | |
| ¹ Crucial limitation for one criterion or some limitations for multiple criteria sufficient to lower ones confidence in the estimate of effect ² Optimal information size not met; small, single study ³ Crucial limitation for one or more criteria sufficient to substantially lower ones confidence in the estimate of effect ⁴ Most information is from studies at moderate risk of bias ⁵ I ² > 40% ⁶ Optimal information size not met ⁷ I ² > 75% | | | | | | | | | | | | |